NASDAQ: NBPNovabridge Biosciences Stock
$1.50-0.07 (-4.46%)
Updated Jun 18, 2026
NBP Price
$1.50
Fair Value Price
$0.11
Market Cap
$173.16M
52 Week Low
$1.46
52 Week High
$6.79
P/E
-3.11x
P/B
0.75x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$46.27M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$21M
Beta
1.31
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NBP Overview
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NBP's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NBP
Ranked#315 of 465
Ranked#315 of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important NBP news, forecast changes, insider trades & much more!
NBP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NBP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NBP ($1.50) is overvalued by 1,322.22% relative to our estimate of its Fair Value price of $0.11 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NBP ($1.50) is not significantly undervalued (1,322.22%) relative to our estimate of its Fair Value price of $0.11 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NBP due diligence checks available for Premium users.
Valuation
NBP fair value
Fair Value of NBP stock based on Discounted Cash Flow (DCF)
Price
$1.50
Fair Value
$0.11
Overvalued by
1,322.22%
NBP ($1.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NBP ($1.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NBP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.11x
Industry
15.77x
Market
9.47x
NBP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.75x
Industry
4.95x
NBP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NBP's financial health
Profit margin
Revenue
$0.0
Net Income
-$30.8M
Profit Margin
0%
NBP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$260.5M
Liabilities
$29.6M
Debt to equity
0.13
NBP's short-term assets ($217.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NBP's short-term assets ($217.52M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NBP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NBP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.6M
Investing
$0.0
Financing
-$3.0M
NBP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NBP vs Biotech Stocks
Novabridge Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.